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Purpose: Although aspirin therapy is used widely in older adults for prevention of cardiovascular
disease, its impact on the incidence, progression and severity of age-related macular degeneration
(AMD) is uncertain. The effect of low-dose aspirin on the course of AMD will be evaluated in this
clinical trial.
Design: A sub-study of the ‘ASPirin in Reducing Events in the Elderly’ (ASPREE) trial, ASPREE-AMD is a
5-year follow-up double-blind, placebo-controlled, randomized trial of the effect of 100 mg daily aspirin
on the course of AMD in 5000 subjects aged 70 years or older, with normal cognitive function and
without cardiovascular disease at baseline. Non-mydriatic fundus photography will be performed at
baseline, 3-year and 5-year follow-up to determine AMD status.
Primary outcome measures: The incidence and progression of AMD. Exploratory analyses will deter-
mine whether aspirin affects the risk of retinal hemorrhage in late AMD, and whether other factors,
such as genotype, systemic disease, inﬂammatory biomarkers, inﬂuence the effect of aspirin on AMD.
Conclusion: The study ﬁndings will be of signiﬁcant clinical and public interest due to a potential to
identify a possible low cost therapy for preventing AMD worldwide and to determine risk/beneﬁt
balance of the aspirin usage by the AMD-affected elderly. The ASPREE-AMD study provides a unique
opportunity to determine the effect of aspirin on AMD incidence and progression, by adding retinal
imaging to an ongoing, large-scale primary prevention randomized clinical trial.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author. ASPREE study, DEPM, Monash University, 99 Commercial Rd, Melbourne, VIC, 3004, Australia.
E-mail addresses: liubov.robman@monash.edu (L. Robman), rh.guymer@unimelb.edu.au (R. Guymer), robyn.woods@monash.edu (R. Woods), stephanie.ward@monash.
edu (S. Ward), rory.wolfe@monash.edu (R. Wolfe), james.phung@monash.edu (J. Phung), labh@unimelb.edu.au (L. Hodgson), galinam@unimelb.edu.au (G. Makeyeva),
kzaung@unimelb.edu.au (K.Z. Aung), tom.gilbert@monash.edu (T. Gilbert), jessica.lockery@monash.edu (J. Lockery), y-anh.lepham@monash.edu (Y.-A. Le-Pham), suzanne.
orchard@monash.edu (S. Orchard), elsdon.storey@monash.edu (E. Storey), Walter.P.Abhayaratna@act.gov.au (W. Abhayaratna), daniel.reid@monash.edu (D. Reid), michael-
ernst@uiowa.edu (M.E. Ernst), Mark.Nelson@utas.edu.au (M. Nelson), chris.reid@monash.edu (C. Reid), John.McNeil@monash.edu (J. McNeil).
1 The full list of the ASPREE Investigator Group is provided in the ASPREE Methodology paper, ref [44].
Contents lists available at ScienceDirect
Contemporary Clinical Trials Communications
journal homepage: www.elsevier .com/locate/conctc
http://dx.doi.org/10.1016/j.conctc.2017.03.005
2451-8654/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contemporary Clinical Trials Communications 6 (2017) 105e114
1. Introduction
Age-related macular degeneration (AMD) is a major cause of
visual impairment and legal blindness amongst the elderly in
developed countries [1e4]. Visual impairment from AMD leads to a
loss of quality of life, with increased rates of depression, injury,
social isolation and institutionalization. AMD is strongly associated
with age, to the extent that more than 10% of adults aged over 80
are living with advanced AMD. Increasing life expectancy was
estimated to double the number of people with this late-onset
disease over the next two decades, with a substantial impact on
quality of life and the costs of care [5e7]. The late forms of AMD
lead to central vision loss as a result of neovascular (nAMD) com-
plications or atrophic changes (geographic atrophy) in the retina.
Anti-vascular endothelial growth factor (anti-VEGF) therapy has
signiﬁcantly improved the outcomes for nAMD, but there remains
no proven treatment to speciﬁcally slow progression of geographic
atrophy (GA). There is also no speciﬁc treatment that prevents
progression from early or intermediate AMD to late AMD. Current
recommendations, which are of limited efﬁcacy, are centred upon
the use of supplements, lifestyle and dietary advice [8e11]. As
populations age, there is an imperative to delay the onset and
progression of disability and chronic disease. Identifying an effec-
tive preventive agent for AMD, or one that can slow its progression,
would have signiﬁcant beneﬁcial effects on quality of life as well as
healthcare costs.
2. Rationale for the ASPREE-AMD study: a potential for
aspirin to prevent or slow the AMD process
Inﬂammatory processes have been implicated in the patho-
genesis of AMD and its progression and AMD is considered bymany
to be a chronic, systemic inﬂammatory disease [12e16]. As such it is
plausible that aspirin, via its anti-inﬂammatory actions, may play a
role in both the prevention and slowing of progression to vision loss
through low grade inﬂammatory process. This was the rationale for
two previous sub-studies in large primary prevention trials of low
dose aspirin that evaluated self-reported AMD incidence as a sec-
ondary outcome. In these trials, alternate-daily aspirin versus pla-
cebo was administered in a population of 22,071 US physicians
aged 40e84 years, with 5 years of follow-up [17] and in a popula-
tion of 39,876 women aged over 45 years, with 10 years of follow-
up [18]. Both studies reported a similar effect size of low dose
aspirin in reducing the relative risk of visually signiﬁcant AMD by
more than 20%. The studies used self-reported diagnoses,
conﬁrmed with medical record data, in order to reduce random
misclassiﬁcation. While both studies are suggestive of a beneﬁcial
effect of aspirin with respect to AMD, the reliance on self-reported
diagnosis and the low signiﬁcance of the results due to the low
number of incident cases in the relatively young study populations
limit the weight that can be given to this evidence.
Results from observational studies with respect to aspirin's in-
ﬂuence on AMD incidence and prevalence have been inconsistent,
ranging from the generally positive (‘harmful’) associations with
AMD prevalence or incidence, with emphasis on the increased
frequency of sub-retinal or vitreous hemorrhages [19e24], to no
association [25e32], to negative (‘protective’) association [33,34].
(Table 1). Thus, the overall risk/beneﬁt balances of aspirin in rela-
tion to incidence and prevalence of AMD are yet to be fully
explored. In addition, if aspirinwere to increase the risk of retinal or
vitreous hemorrhage, this ﬁnding would have important implica-
tions when considering aspirin for widespread use in primary
prevention. A growing need for a sufﬁciently powered randomized
controlled trial to resolve the relationship between aspirin use and
AMD was highlighted in several recent reviews and meta-analyses
[23,35e43]. The NIH-funded large randomized controlled trial -
ASPirin in Reducing Events in the Elderly (ASPREE) - designed to
address the role of aspirin in primary prevention on disability- and
dementia-free survival in older adults, provides the opportunity for
a sizable sub-study to address this need [44]. Taking into account
the likelihood that a number of actions of aspirin (anti-inﬂamma-
tory, anti-platelet, etc.) are likely to be seen with 100 mg daily in
ASPREE, its effect could bemultifaceted. Thus, alongwith the tested
possible preventive effect by suppressing the inﬂammatory process
at earlier stages of AMD, aspirin's antiplatelet property might
appear to be exacerbating the late AMD processes. This phenom-
enon will be closely looked into. Adding fundus photography to
examine a sub-set of ASPREE participants, the ASPREE-AMD sub-
study will determine the effect of low-dose aspirin on the course of
AMD.
3. Material and methods
3.1. Study design
This study is a 5-year follow-up, double-blind, randomized
placebo-controlled trial of daily 100 mg aspirin versus placebo on
the incidence and progression of AMD, in a population of healthy
Australians aged 70 years or older. ASPREE-AMD is a sub-study of
the principal ASPREE trial.
3.1.1. Ethics statement
The ASPREE-AMD study has been approved by the Human
Research and Ethics Committee of Monash University, undertaken
according to the Helsinki Declaration for research on humans and
registered with the Australian New Zealand Clinical Trial Registry:
ACTRN 12613000755730. The principal ASPREE study is registered
with the International Standardized Randomized Controlled Trials
Register, ASPirin in Reducing Events in the Elderly, Number:
ISRCTN83772183 and clinicaltrials.gov, Number NCT01038583.
ASPREE participants consented separately to retinal photog-
raphy. Participants in two other sub-studies of ASPREE, which
together include more than 900 ASPREE participants with retinal
photographs taken with the same cameras at baseline and after 3
years of treatment with study medication, will also be included in
the ASPREE-AMD sub-study. These two sub-studies are:
(1) ENVISion (Aspirin for the prevention of cognitive decline in
the Elderly: a Neuro-Vascular Imaging Study - a two-centre,
randomized, double-blind, placebo controlled trial of the
effects of daily 100 mg enteric-coated aspirin on the rate of
increase of magnetic resonance imaging (MRI)-based white
matter hyperintensities (WMH) and silent brain infarctions
(SBI), ACTRN12609000613202) [45];
(2) SNORE-ASA (Study of Neurocognitive Outcomes, Radiolog-
ical and retinal Effects of Aspirin in Sleep Apnoea - a multi-
centre, randomized, double-blind, placebo controlled trial
of the effects of daily 100 mg enteric-coated aspirin on
cognitive outcomes in the setting of sleep apnoea, in healthy
older adults aged 70 and over, ACTRN 12612000891820).
The year 5 follow-up photography for these participants will be
conducted as part of the ASPREE-AMD study.
3.1.2. The principal ASPREE trial
ASPREE is a multi-centre, randomized, double-blinded, placebo-
controlled trial of daily 100 mg enteric-coated aspirin in
19,000þ healthy community dwelling older adults in Australia and
the US. Age eligibility is 65 years and over for African Americans
and Hispanics in the USA, and 70 years and over for all others,
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Table 1
Studies of the association between regular aspirin intake and the course of age-related macular degeneration (AMD).
Reference Details of study Conclusion
Case studies
el Baba, F. 1986 [19] 15 AMD cases of massive subretinal or vitreous
hemorrhages. Of them, 4 onWarfarin, 1 on Aspirin, 1 on
Clinoril and 1 on Ibuprofen. Doses of medications not
provided.
Combining the author's cases with cases published before, 16/
83(19%) of patients were on eitherwarfarin (n¼ 14) or aspirin
(n ¼ 2).
Case-control studies and retrospective studies
Wilson, H.L. 2004 [33] Retrospective consecutive case series of diagnosed AMD
patients: 104 CNV, 18 GA and 204 intermediate AMD.
Doses not provided.
Regular aspirin use [more than 6 months (LR assumption)] was
associated with the decreased rates of CNV in the
Multipredictor Model (hazard ratio ¼ 0.63, 95% CI ¼ 0.40e0.98,
p ¼ 0.04).
Kiernan, D. F. 2010 [24] Retrospective cross-sectional study. Incident CNV:
n ¼ 195 eyes of 195 patients examined over 5 years. 80
(41%) used daily aspirin during a median follow-up of
27.0 months (range, 1e73 months). Doses not provided.
Incident intraocular hemorrhages (subretinal or vitreous) in
patients with neovascular AMD were associated with daily
antiplatelet or anticoagulant (AP/AC) medication usage (aspirin,
clopidogrel, and warfarin). Aspirin was independently
associated with hemorrhages, with OR 3.75 (95% CI 1.88e7.48).
Tilanus, M. A. 2000 [25] Retrospective case-control study: 50 cases withmassive
haemorrhages (15 on Warfarin and 8 on aspirin) vs 50
cases with small AMD-related hemorrhages (2 on
warfarin and 6 on aspirin)
Aspirin doses varied from 80 to 100 mg daily.
Aspirinwas not associatedwith massive hemorrhages in AMD,
whilst warfarin was associated.
Jonczyk-Skorka, K. 2015
[26]
Case-control study: n ¼ 292; 80 with drusen, 25 with
GA, 52 with CNV and 135 controls.
27.1% of study population used aspirin.
Doses not provided.
Aspirin was not associated with any form of AMD
DeAngelis M.M. 2004 [27] Matched case-control study: 73 sibling pairs; one
sibling with CNV, the other with no AMD. Aspirin was
deﬁned as regularly used if taken at least twice per
week for at least 6 months before AMD diagnosis. Doses
not provided.
In this study population of the extremely discordant sibling
pairs, aspirin use was not associated with neovascular AMD
(p ¼ 0.48)
Cross-sectional studies
de Jong, P.T.V.M., 2012 [20] Population-based cross-sectional European Eye Study;
n ¼ 4691, age 65þ
36.4% early AMD and 3.3% late AMD
Frequency of aspirin analysed: at least once monthly
(n ¼ 1786), weekly (n ¼ 326) and daily (n ¼ 839). Doses
not provided.
For daily aspirin users (17.3% of population), aspirin was
associatedwith prevalent AMD. AMD grade 1: OR 1.26 (95% CI,
1.08e1.46); AMD grade 2: OR 1.42 ( 95% CI, 1.18e1.70), and
CNV: OR 2.22 (95% CI, 1.61e3.05). For a trend across aspirin
intake frequency p < 0.001.
Cheung, N. 2013 [28] Population-based cross-sectional
Singapore Indian Eye Study; n ¼ 3207.
Aspirin use: yes/no answer to a question “currently
taking any aspirin (solprin, cardiprin, disprin, ecotrin,
but not panadol or dymadon?)”. Doses not provided.
Overall aspirin use was not associated with prevalent early
AMD. Aspirin was associated with early AMD in participants
with a history of cardiovascular disease (OR 2.64, 95% CI 1.31
e5.36) but not without it (OR 0.73; 95% CI 0.36e1.51
(interaction term, p ¼ 0.011).
Chew, E. 2012 [34] Cross-sectional analysis: 2046/4188 (48.8%) AREDS2
participants were taking aspirin; 661 controls (AREDS
Simple Scale Score of 0, 1, and 2), 692 with bilateral
large drusen and pigmentary change in one eye (Score
3), 1369 with bilateral large drusen and bilateral
pigmentary changes (Score 4); 1466 had advanced AMD
in one eye and bilateral large drusen in the other eye
(Score 5). 1304 of the latter group had CNV and 162 had
GA. Aspirin usage: < 5 times per week; > 5 times per
week (<2 per day); or > 5 times per week (2 per day).
In adjusted multivariate analyses, an inverse relationship
between the various stages of AMD with aspirin use at least 5
times a week was found, with OR (95% CI):
for Score 3: 0.82 (0.65e1.02);
for Score 4: 0.86 (0.70e1.05);
for Score 5: 0.62 (0.50e0.76),
for CNV 0.61 (0.49e0.75) and
for GA 0.62 (0.42e0.94).
Rudnicka, A. R. 2010 [29] Case-control study on association between markers of
arterial thrombosis and late AMD: 81 late AMD cases
and 77 controls.
Aspirin was weakly associated with a lower risk of AMD:
Adjusted for age, sex, and smoking, aspirin reduced the risk of
late AMD by 53% (OR 0.47; 95% CI 0.20e1.08); adjusted
additionally for BMI, BP and total serum cholesterol, the OR was
attenuated towards the null (OR 0.61; 95% CI 0.23e1.57).
Cohort studies
Klein, B. E. 2012 [21] Beaver Dam Eye Study e population-based
Cohort: n ¼ 4926 aged 43e86 at baseline; 5-yearly
exams, average 14.8-years of follow-up. Aspirin usage
primary measure (yes/no): at least twice a week
for > 3months, asked at every 5-yr exam. (Doses not
provided).
At the 3rd, 4th and 5th exams, additional info on
frequency (<1 aspirin every second day, 1 every second
day, 1 daily, 2 daily, 3 to 7 daily, or8 daily) and current
dosage was obtained, to calculate an estimated average
daily dose.
Regular aspirin intake was not associated with incidence of
early AMD. Aspirin use 10 years prior to retinal examination
was associated with late AMD (HR ¼ 1.63 [95% CI, 1.01e2.63]),
speciﬁcally with neovascular AMD (HR ¼ 2.20 [95% CI, 1.20
e4.15]).
Liew, G. 2013 [22] Blue Mountains Eye Study e population-based cohort:
n ¼ 2389 Aged 49 years or older; 15 years of follow-up.
Aspirin regular usage:  1 a week in the past year,
conﬁrmed with a list of medications taken for at least 1
month before examination and the medications
brought in. Doses not provided.
Regular aspirin use was associated with developing
neovascular AMD (OR 2.46; 95% CI 1.25e4.83) and was not
associated with the incidence of geographic atrophy.
(continued on next page)
L. Robman et al. / Contemporary Clinical Trials Communications 6 (2017) 105e114 107
including all in the ASPREE-AMD, ENVISion and SNORE-ASA trials
[44]. ASPREE will determine whether 100 mg aspirin daily extends
disability- and dementia-free survival in the elderly, and it is a
primary prevention study. The ASPREE study methods have been
described in detail elsewhere [44]. In brief, the majority of ASPREE
Australian participants have been recruited through partnerships
with general practitioner co-investigators. A minority has been
recruited directly from the community.
The primary endpoint of ASPREE is a composite of death or
dementia (adjudicated according to the DSM-IV criteria) or
Table 1 (continued )
Reference Details of study Conclusion
Sen H. 2007 [31] Age-Related Eye Disease Study (AREDS): 799 of the
1134 subjects in AREDS group 3 and 330 of the 499
subjects in AREDS groups 4 & 5; 11 years of follow-up.
NSAIDs or aspirin usage deﬁned as 5 days of the week
for 3 months. Doses not provided.
Regular systemic use of NSAIDs or aspirin was not associated
with developing advanced AMD
Ying 2016 [30] A Cohort within the Comparison of Age-Related
Macular Degeneration Treatments Trials (CATT):
n ¼ 1165 patients with CNV; 724 (62.1%) patients had
retinal or subretinal hemorrhage at baseline; 514
(44.1%) used antiplatelets, 77 (6.6%) used
anticoagulants, and 17 (1.5%) used both.
Aspirin doses: none (0 mg), 81 mg and 82 mg.
Warfarin doses: none, 1e4 mg and 5 mg.
Duration of use: none (0 mg), <5yrs, 5yrs and <10yrs,
10yrs.
Hemorrhage was present in 64.5% of antiplatelet or
anticoagulant users and in 59.6% of nonusers, OR 1.18; 95% CI
0.91e1.51. Baseline hemorrhages were not associated with
the type, dose, or duration of antiplatelet or anticoagulant use.
Incident hemorrhages 44/1078 (4.1%) were not associated
with antiplatelet or anticoagulant use at baseline (p ¼ 0.28) or
during follow-up (P ¼ 0.64). Among the participants with
hypertension (n ¼ 807), antiplatelet drug use was associated
with a higher rate of hemorrhages at baseline OR 1.43; 95% CI
1.06e1.92.
Aronow, M.E [32]. Observational 6-year AMD progression data from the
AREDS2. 957 aspirin users and 957 non-aspirin users
(n ¼ 1914) matched on the propensity score. Aspirin
regular usage: at least 5 times a week. Doses not
provided.
Aspirin propensity score adjusted for age, was not associated
with AMD progression (OR 0.80, 95% CI 0.41e1.56). Analysed
individually, neither geographic atrophy (OR 1.31, 95% CI 0.52
e3.32) nor CNV (OR 0.60, 95% CI 0.23e1.58) was associated
with the aspirin propensity score.
Randomized controlled trials
Christen, W. G. 2001 [17] 5-year RCT of low-dose aspirin (325 mg every other
day) and beta carotene (50 mg every other day) among
US physicians; n ¼ 22,071
Aspirin intake was not associated with self-reported AMD, RR
0.77; 95% CI 0.54e1.11. Additional testing for a potential
beneﬁcial effect in randomized trials of adequate size and
duration is required; due to relatively young age of population,
the detection of 23% risk reduction was not statistically
signiﬁcant
Christen, W. G. 2009 [18] 10-year RCT of low-dose aspirin (100 mg every other
day), US female health professionals; n ¼ 39,876
Aspirin intake was not associated with self-reported AMD,
Hazard ratio 0.82; 95% CI, 0.64e1.06.
ASPREE Investigator Group
2013
[44]
Australian-American RCT “ASPirin in Reducing Events in
the Elderly (ASPREE). n¼ 19.000, aged 65 years or above
(“US minorities”) and 70 years or above (non-“US
minorities”)
100 mg of aspirin daily.
Design: In contrast to other aspirin trials that have largely
focused on one disease/group of diseases, ASPREE has a unique
composite primary endpoint ‘disability free survival’, to capture
the overall risk and beneﬁt of aspirin, aiming to extend healthy
independent lifespan. Pending results.
Meta-analyses
Kahawita, S. K. 2014 [41] 2 cross-sectional, 1 population-based incidence and 1
cohort study; n ¼ 10,292
High heterogeneity was emphasized. Aspirin use was
associated with early ARMD. Pooled OR 1.43 (95%CI 1.09e1.95)
Ye, J. 2014 [40] 2 RCTs, 3 cohorts and 4 case-control studies
n ¼ 177,683
Aspirin use in total was not associated with AMD in total.
Neovascular AMD was associated with aspirin use: RR 1.59;
95% CI 1.09e2.31
Zhu, W 2013 [35] 2 RCTs, 4 case-control and 4 cohort studies
n ¼ 171,729
Aspirin use was not associated with increased risk for Any
ARMD (pooled RR 1.09, 95%CI 0.96e1.28), and it was so for
either early or late AMD, in RCT case-control or cohort studies.
Li, L. 2015 [23] Ten studies. N ¼ 180 834. 2 Cohorts, 2 RCTs, 2 cross-
sectional, 4 case-controls
Weakly, but statistically signiﬁcantly, aspirin use was
associated with AMD, with the pooled RR of 1.137 (95% CI,
1.003e1.289; I(2), 68.4%). The pooled RR was 1.19 (95% CI, 0.92
e1.53; I(2) 82.6%) for early AMD, 1.95 (95% CI, 1.40e2.72; I(2),
27%) for CNV and 0.84 (95% CI, 0.62e1.15; I(2), 0%) for GA.
Reviews
Sobrin, L. 2013 [37] Analysis of ﬁndings and limitations of two RCTs, two
population-based cross-sectional studies, one cohort
and one case-control study.
Current data on the association between aspirin use and AMD
do not fulﬁl criteria to declare that a causal relationship
exists. The criteria that are not met include consistency,
sufﬁcient strength of association and speciﬁcity.
Wu,Y 2013 [36] Aspirin and Age Related Macular Degeneration; the
Possible Relationship. Review of multiple studies.
Evidence from the epidemiological studies has been
contradictory and no persuasive conclusions have been made.
“The current results should be challenged and acknowledged
by well-designed, large-scale and long term follow-up
studies”
Christen, W.G. 2014 [42] Aspirin and risk of Neovascular AMD. Review of
multiple studies.
The inherent limitations of observational studies preclude an
interpretation of causality. Well-designed randomized trials
of sufﬁcient size and duration are needed to establish risk/
beneﬁt ratio of aspirin use by individuals at low-to-moderate
risk of cardiovascular disease.
Chong, E.W. 2014 [39] Aspirin and risk of AMD. Review-Commentary Discussed the controversy surrounding aspirin use and
highlighted the ongoing randomized controlled trial ASPREE.
Abbreviations: AMD, age-related macular degeneration; RCT, randomized controlled trial; GA, geographic atrophy; CNV, choroidal neovascularisation; OR, odds ratio; RR,
relative risk; CI, conﬁdence interval.
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persistent loss of one of the basic activities of daily living. Pre-
speciﬁed secondary endpoints include death, cardiovascular and
cerebrovascular disease, cancer, cognitive impairment, depression,
physical disability and clinically signiﬁcant bleeding. Clinical end-
points are adjudicated by independent committees provided with
de-identiﬁed clinical information about the event [44]. Inclusion
criteria include men and women who were able to give informed
consent and able to attend a study visit for an estimated period of
ﬁve years. Exclusion criteria include a past history of cardiovas-
cular event or established cardiovascular disease (including stroke,
transient ischemic attack, myocardial infarction, unstable angina,
coronary artery reperfusion procedures and bypass grafting,
abdominal aortic aneurysm, cardiac failure), atrial ﬁbrillation, de-
mentia or score of <78 on Modiﬁed Mini-Mental State (3MS) ex-
amination, disability as deﬁned by severe difﬁculty or inability to
perform any of the 6 Katz Activities of Daily Living (ADLs) [46], a
condition with a high current or recurrent risk of bleeding,
anaemia, a condition likely to cause death within 5 years, current
use of other antiplatelet or antithrombotic medication, current use
of aspirin for secondary prevention, and uncontrolled
hypertension.
Participants meeting initial ASPREE eligibility at a screening
study visit underwent a four-week placebo run-in phase and those
with compliance equal or greater than 80% were randomized.
Randomization of study drug followed a block randomization
procedure and was stratiﬁed by site and age (65e79 and 80
years). An independent statistician generated the randomization
list using the STATA ‘ralloc’ procedure. Participants were random-
ized to receive either 100 mg of enteric-coated aspirin or enteric-
coated placebo, which are identical in appearance, in a ratio of 1:1.
A 12-month supply of studymedicationwas dispensed at trial entry
and thereafter at each annual visit. Study participants, investigators
and general practitioner co-investigators remain masked to treat-
ment allocation.
All ASPREE participants have face-to-face study visits annually,
with quarterly telephone contact in between visits. The 6-month
phone call ascertains additional information relevant to study
endpoints, including persistence of functional impairment.
Annual ASPREE data collected and assessments conducted
include: demographics, cognitive function, physical function,
quality of life, blood pressure, cardiovascular biomarkers, health
behaviours and lifestyle (Table 2). Compliance with study medica-
tion is checked by annual pill count. Clinical endpoints of the study
are being adjudicated and conﬁrmed. The ASPREE study began in
2010 and completed recruitment in December 2014, with 16,703
participants in Australia and 2411 in the USA, and will conclude in
2017/2018.
3.1.3. The ASPREE-AMD trial
The ASPREE-AMD trial involves the acquisition of digital retinal
images of both eyes at baseline, 3 and 5 years in ASPREE partici-
pants after randomization to aspirin or placebo.
All Inclusion criteria for the parent ASPREE study applied to
this project. All consecutive randomized ASPREE participants at
each centre who also gave informed consent for retinal photog-
raphy and were able to attend a retinal photography visit were
deemed eligible for entry into the ASPREE-AMD sub-study.
All Exclusion criteria for the parent ASPREE study also
applied, with the additional criterion of the examiner being un-
able to view the macula without pharmaceutical dilation to take a
retinal image (mainly due to either ocular media opacity or small
and rigid pupil).
Participants with bilateral late AMD at baseline were still
enrolled, but will be excluded from the analysis of AMD incidence
or progression. These participants will be followed up for assess-
ment of the potential worsening of the condition due to possible
new or recurrent hemorrhage.
3.1.4. Retinal photography
Two digital, 45, non-stereoscopic, colour retinal photographs of
each eye, with one image centred on the fovea and one on the optic
disc, are taken on one of nine non-mydriatic fundus cameras
(Canon Inc., Tokyo, Japan), using Digital Health Care software (UK).
Non-mydriatic digital retinal imaging has been proven to be a
reliable method of AMD detection [47e49]. These fundus cameras
are either (1) located permanently at four ASPREE study stationary
centers in three Australian states, or (2) installed permanently in
the speciﬁcally designed three high-roofed clinic vehicles (Mer-
cedes vans) operated from the Melbourne site to engage partici-
pants from remote regional and rural areas in the study, or (3)
shipped on the regular basis in the ﬂight cases from Melbourne to
the most distant areas, with trained research staff travelling to and
assembling the cameras at the pre-organized sites. The use of
several mobile photographic units allowed involvement of rural
and regional Australian population in this research.
Photographs are taken without pharmacological pupil dilation.
The right eye is photographed ﬁrst, with sufﬁcient time (up to
5 min) allowed between the following photo shots for the pupils to
Table 2
Schedule of the ASPREE-AMD study and relevant components of the ASPREE trial.
Timeline Baseline
2010e14
3-yr follow-up 2013-17 5-yr follow-up
2015e20
ASPIRIN and AMD
Retinal photography X X X
Screening for medically signiﬁcant pathology X X X
Grading digital images for AMD X X X
Analysis of grading results X X
Medicare request on anti-VEGF intravitreal injections X
Genotyping for AMD-related genes (further research) X
Analysis and Reporting X (2020-21)
ASPREE TRIAL
Recruitment, Screening and Baseline enrolment X
Demographics, Cognitive & Physical Measurementsa X X
Blood Pressure and Cardiovascular Biomarkersb X X
Health Behaviours and Lifestyle Measurementsc X X
Reporting X (2018e2019)
a First language, education, height, weight, abdominal circumference, family history and co-morbidity, cognitive and physical function measurements, depression measure.
b Total cholesterol, LDL-C, HDL-C, triglycerides, Hb, fasting glucose & creatinine, UACR.
c Physical ability, smoking history, alcohol use; SF-12, IADL, ADL.
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recover from ﬂash-induced constriction. Staff members were
trained to assess image quality and re-capture if images are un-
satisfactory. The images and participant identiﬁers are backed up
on the portable hard discs and bulk-exported from each camera on
a monthly basis. Prior to uploading the images to the ASPREE
database, the batches of the exported images are converted into
JPEG format and labelled (each image) with the participants' data
entered into the computers linked to the fundus cameras, using
for both procedures a custom-written script for automated bulk
processing. Four pre-speciﬁed identiﬁers (participant ID, acrostic
that consists of the combination of the shortened last and ﬁrst
names, date of imaging and DHC code) are used to match images
with the ASPREE database records of the participants during bulk
uploading of the images. The batches of images are initially
screened for signs of clinically signiﬁcant pathology requiring
medical attention and if needed, the notiﬁcation letters, auto-
matically generated via the ASPREE database, are sent to the
participants and their general practitioner. De-identiﬁed images
are transferred to the ASPREE-AMD retinal image database
housed on a secure server for detailed grading. Images are graded
for AMD according to the Beckman classiﬁcation by two inde-
pendent, masked experienced graders [50]. Grading process
closely follows the timing of image acquisition, aiming to com-
plete the grading soon after completion of image collection.
During side by side grading, the temporal sequence of photos will
not be masked. In this study, the image labels include the date of
photography as one of the identiﬁers important for data valida-
tion. Deleting the dates and relabelling the images would increase
risk of errors, mostly due to the large scale of the study. However,
the graders will at all times be independent of each other and
masked to the allocation of study medications.
The graders assess quality of the image (for focus and ﬁeld
placement), as well as the presence, size and location of the AMD-
related lesions within a 6000 mm circular grid calibrated for size on
the optic disc and centred on the fovea [47]. Grading is checked
periodically for inter-grader agreement and intra-grader repeat-
ability on random selections of images.
Incident pathology or cases of progressionwill be conﬁrmed via
side-by-side comparison of baseline and follow-up images from the
same participant and adjudicated by an ophthalmologist (RG)
when required. After assessment of the baseline and follow-up
retinal images for incidence, progression and severity of AMD, the
effect of aspirin on the course of AMD will be analysed.
3.1.5. Adverse events
All adverse events and serious adverse events are reported ac-
cording to good clinical practice guidelines and handled by the
principal ASPREE study. An independent Data and Safety Moni-
toring Board (DSMB), established by the National Institute on Ag-
ing, monitors all ASPREE activities on a 6 monthly basis. Clinically
signiﬁcant retinal pathology at baseline or follow-up is reported
back to the participant's primary care physician and to the partic-
ipant. Participants with any bleeding disorder, including retinal
hemorrhage, may be taken off study medication.
3.1.6. Acquisition of additional information on adverse events and
anti-VEGF treatment
In the last decade, intravitreal anti-VEGF therapy for choroidal
nAMD has been implemented in Australia. Once treated with anti-
VEGF, signs of nAMD may not be visible on colour fundus images.
Therefore, to improve the accuracy of diagnosis and correctly
identify those who are receiving treatment with intravitreal rani-
bizumab and aﬂibercept between ASPREE-AMD baseline and
follow-up time points, additional informationwill be obtained from
two sources to ensure the development of nAMD is captured:
participant self-reported adverse events validated through medical
records and the National Medicare data on intravitreal ranibizumab
and aﬂibercept prescriptions being approved for nAMD treatment
during the study period. These data will not capture those partic-
ipants who are being treated with bevacizumab, an off label drug
used for nAMD. As ranibizumab and aﬂibercept are fully subsidized
through the pharmaceutical beneﬁts scheme (PBS) in Australia for
treatment of subfoveal nAMD, treatment with bevacizumab is
likely to be uncommon. As anti-VEGF treatment via the PBS is used
now for other retinal conditions as well, the diagnosis of AMD will
be validated via medical records and the collected data on adverse
events.
The data on anti-VEGF medications for nAMD will be collected
for all ASPREE participants (not just those in ASPREE-AMD), as
consent for their retrospective information to be obtained from
Medicare is included in the ASPREE protocol, and this will provide
an additional opportunity to conduct analysis on the effect of
aspirin on the incidence of nAMD on a sample which will be
considerably larger than the sample photographed as part of
ASPREE-AMD.
3.1.7. Deﬁnitions of AMD
The following Beckman risk categories of AMD will be used in
the analysis [50]:
 No apparent aging change: no drusen and no AMD pigmenta-
tion abnormalities
 Normal aging changes: only drupelets (small drusen <63 mm)
and no AMD pigmentation abnormalities
 Early AMD: Medium drusen (63 mm - <125 mm) with no AMD
pigmentation abnormalities
 Intermediate AMD: Medium drusen (63 mm - <125 mm) with
AMD pigmentation abnormalities or large drusen (125 mm)
 Advanced AMD: neovascular AMD (nAMD) or geographic
atrophy
3.1.8. Primary outcome measures
1) Incident AMD. Any case that progresses from bilateral
‘normal’ or ‘normal aging change’ to any grade of AMD in at least
one eye will be classiﬁed as incident AMD.
2) Progression of AMD. An increase in the AMD severity status
from early or intermediate AMD in either eye will be classiﬁed as
AMD progression. Regression of AMD stage will also be
documented.
3.1.9. Future genetic and inﬂammatory biomarker analyses
Another sub-study of the principal ASPREE study, the ASPREE
Healthy Ageing Biobank (www.aspree.org), in parallel with
ASPREE-AMD, collects, processes and stores components of blood
and urine samples at baseline and at year 3 in the trial, with serum,
EDTA plasma, sodium citrate plasma, red blood cells and buffy coat
aliquots stored for future biomarker and genotyping analysis. As-
sociation studies will be conducted in relation to potential
biomarker variables (inﬂammatory markers, AMD-related genetic
polymorphisms) and AMD incidence and progression, as well as
their possible inﬂuence on the effect of aspirin on the primary
outcomes.
3.2. Statistical analysis
3.2.1. Sample size and study power
No single population-based study provided all relevant infor-
mation that we required for sample size calculations, hence we
used data from several studies.
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Prevalence estimates: we used the results from the cross-
sectional European Eye Study, conducted on participants of
similar ethnic origin and similar age (65 years or older), and also
used digital images of the retina [51]. The study found that
approximately half of the participants had no AMD, about one third
had medium drusen (early AMD) and about 15% had large drusen
(intermediate AMD).
From an expected sample of 5000 ASPREE-AMD participants
with gradable images at baseline, excluding an estimated 2% with
existing ‘late AMD’ at baseline and allowing for a 4% per annum
attrition, the cohort will have 3995 participants at 5-year
follow-up.
Incidence estimates: Based on the age-speciﬁc data (70e79 and
80þ years) from the population-based longitudinal Melbourne
Visual Impairment Project (VIP), also conducted in Victoria,
Australia, among an estimated 1998 participants with no AMD at
baseline (estimated to be 50% of 3995 followed-up participants),
the expected 5-year incidence of early and intermediate AMD
(combined) is approximately 20% [52].
Progression estimates:
(i) Among an estimated 1398 participants with early AMD
(medium size drusen) at baseline (35% of 3995 participants),
we expect 35% to have 5-year progression to intermediate
AMD. For this estimate we used the only available data - the
AREDS study ﬁnding that medium sized drusen (63e125 mm)
progress in ﬁve years to large drusen (125 mm) at the rate of
20% if drusen are in one eye only and at the rate of 50% if
drusen are in both eyes [50]. As there is no data on the
proportion of unilateral and bilateral drusen in a population
aged 70 years or older, we took an average of 35%.
(ii) Among an estimated 1998 participants with either early
AMD or intermediate AMD at baseline, we expect at least 4%
to progress to late AMD, based on the published late AMD
incidence rates amongst people 70 years or older in two
longitudinal studies, the Melbourne VIP and Blue Mountains
Eye Study (BMES), both conducted in the Australian popu-
lation [52,53].
Based on these estimates, our study will provide 80% power
with two-sided alpha of 0.05 to detect: (1) 24% reduction of early/
intermediate AMD incidence, (2) 20% reduction of progression from
early to intermediate stage of disease and (3) 53% reduction of
progression from early or intermediate stage to late stage.
The detectable 5-year changes between the placebo and aspirin
treatment groups in incidence and progression of AMD are pro-
vided in Table 3. Competing risks of death and debilitating diseases
that might cause differential survivorship in study arms will be
considered in the analysis [54,55].
Our power calculation describes percent reductions that can be
detected with 80% power based on the observed effects, which are
innately weaker than the “true” effect that could exist if everyone
remained on their randomized treatment. Therefore, a naturally
occurring incomplete compliance has been incorporated in the
estimates. The reasons for non-compliance include the develop-
ment of a non-fatal, non-disabling cardiovascular or cerebrovas-
cular event necessitating aspirin therapy. Thus, the ASPREE
protocol speciﬁes an expectation that 5% per annum of placebo-
group participants will initiate aspirin use and similarly that 5%
of aspirin-group participants will cease taking study medication
and not commence open-label aspirin use.
3.2.2. Statistical analysis plan
The primary analyses will be conducted using the intention-to-
treat principle, i.e. according to the group to which participants
were randomized and without reference to their actual compliance
with assigned treatment. We will use the grading data from the
participants with baseline and 5-year images and apply log-
binomial regression models to directly compare event rates be-
tween treatment groups, to assess the effect of aspirin on the
outcomes: AMD incidence and progression. Each model will be
applied to the relevant eligible participant subset (see Table 3 for
expected numbers) and the models will include a binary covariate
to indicate randomization to aspirin or placebo; the parameter for
this covariate can be translated as the estimated rate ratio for
aspirin.
Secondary analyses will apply the same models but with
adjustment for age, sex and smoking status at baseline, and further
analyses will also adjust for any variables predictive of AMD pro-
gression and found to be different between the two groups at
baseline.
An exploratory analysis will be undertaken to determine
whether aspirin is associated with increased risk of retinal
hemorrhages.
Given the large sample size, we anticipate that randomization
will adequately balance baseline characteristics of participants
between the two treatment groups. However, the use of aspirin
may affect survivorship itself, which plays a major role in AMD
statistics. Therefore, if the follow-up loss of retinal data due to
death and disability is found to be unbalanced between the study
arms, it will be included in the statistical model as a competing risk
[55].
To assess sensitivity to participant dropout, the analyses will be
repeated within a multiple imputation process, in which the
imputation model will include 3-year image information, baseline
characteristics and 5-year outcomes. Additionally, an analysis will
be undertaken using baseline, 3-year and 5-year information from
each participant in mixed effect models that are extensions of the
Table 3
Detectable risk reduction (%) in 3995 participants with gradable images free of late AMD at baseline in cumulative 5-year incidence or progression of AMD.
Outcome Patient subset at risk
(sample size)
5 years follow-up
Incidence rate in
placebo group (%)
Detectable rate ratiob
(aspirin rate/placebo rate)
Power 80% Power 90%
Incidence of Early or Intermediate AMD No AMD at baseline
N ¼ 1998a
20 0.76 0.73
Progression from early to Intermediate AMD Early AMD at baseline
N ¼ 1398a
35 0.80 0.77
Progression from early or intermediate to Late AMD Early/ Intermediate AMD at baseline
N ¼ 1998a
4 0.47 0.40
a Estimated from the sample size calculation.
b Based on 1:1 allocation of aspirin and placebo, power 80% or 90%, two-sided alpha of 0.05.
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log-binomial regression models with the inclusion of a random
effect for participant to allow for intra-person correlation in
outcome over time.
A ‘per protocol’ analysis will also be conducted for each outcome
using the recorded data on study drug compliance and
commencement of open-label aspirin use during follow-up with
the aim of estimating complier-averaged causal effects of aspirin.
The results of both Intention-To-Treat and “per protocol” analyses
will be reported.
3.2.3. Pre-speciﬁed sub-group analyses
Subgroup analyses will use interaction terms involving the
randomization covariate to examinewhether variations in systemic
diseases and inﬂammatory biomarker status inﬂuence the effect of
aspirin on AMD. Pre-speciﬁed subgroup analyses will be under-
taken by age and smoking status:
a) Age below and above study median: The balance of the AMD-
related risks and beneﬁts due to aspirin may differ between
age groups as a result of different rates of mortality, cardiovas-
cular risk, cognitive decline, other disability and risk of adverse
effects.
b) Smoking: Current versus Never or Former smokers. Smoking is a
major well-proven external risk factor for AMD. The effect of
aspirin may be different in smokers and non-smokers.
Reporting of aspirin effects will be stratiﬁed by any covariate
found to hold an interaction with the randomization variable.
We will also look in the future at common genetic variants
associated with AMD and determine if the effect of aspirin was
inﬂuenced by the genotype.
4. Discussion
In addition to its anti-inﬂammatory, antipyretic and analgesic
qualities, aspirin, as a drug proven for the secondary prevention of
occlusive cardiovascular events, has become the world's most
widely used pharmaceutical drug, particularly by older adults. AMD
is the most common cause of vision impairment in people over the
age of 50 years in our community and it has profound effects on
vision and quality of life. The ASPREE-AMD randomized clinical
trial provides a unique opportunity to examine whether long-term
low-dose aspirin inﬂuences the incidence or progression of AMD.
Aspirin is established for the management of acute cardiovas-
cular diseases (CVD) and their secondary prevention [56e59]. The
role of aspirin in primary prevention of CVD is less deﬁned and is
currently under further investigation [44,54,60e64]. Nevertheless,
it is widely used by older adults, with 20%e50% of older persons in
the USA, without cardiovascular disease, being regular users of
aspirin [65,66]. The role of low dose aspirin in cancer prevention
and management is also under investigation [65,67e70].
A number of studies have been undertaken to establish the as-
sociation of aspirinwith the incidence and progression of AMD, but
the results have been inconsistent. Self-reported data from two
large randomized controlled trials suggest a beneﬁcial effect of
aspirin on AMD [17,18]. Recently, considerable publicity was given
to the results of cross-sectional and cohort studies, which reported
that aspirin exacerbated the AMD process and contributed to
blindness [20e22]. In the latest report from the BlueMountains Eye
Study (BMES), the 15-year cumulative nAMD incidence was 9.3% in
aspirin users and 3.7% in nonusers. Users were deﬁned as those
who took aspirin (doses were not recorded) once or more per week
in the year before the baseline. Adjusted for age, sex, smoking,
history of cardiovascular disease, systolic blood pressure, and body
mass index, nAMD was associated with regular use of aspirin (OR
2.46; 95% CI, 1.25e4.83). In this study, aspirin use was not updated
at follow-up examinations and the systemic survival bias could
have affected the results, as 46% participants from the original
BMES cohort were not available for the 15-year follow-up. Aspirin
users may have had prolonged survival rates allowing them to
develop AMD. Competing risks of deathwere not adjusted for in the
BMES study. Thus, the risk/beneﬁt proﬁle of aspirin use with
respect to AMD remains unanswered. These issues are important
given that aspirin is already the world's most widely used thera-
peutic agent, being taken regularly by more than 100 million in-
dividuals [71].
The principal ASPREE trial will be informative on the use of
aspirin in primary prevention of death, physical and cognitive
disability in an elderly population, whilst ASPREE-AMD will clarify
whether aspirin is efﬁcacious as a primary prevention for AMD and
useful in slowing its progression. Additionally, it will allow the
question regarding a possible increased risk of retinal hemorrhage
associated with nAMD to be addressed. The ASPREE-AMD study
differs from other studies in that it is a randomized controlled trial,
with photo-documented detailed AMD assessment and a large
sample size in the at-risk, relatively healthy, participants aged 70
years or older. The strong detailed records of the exposure data,
which include checking the routine of pill taking at every 3-
monthly phone calls and counting untaken pills in the returned
containers, add weight to the study merit.
As part of ASPREE, other health outcomes will be captured,
which can be used when interpreting the ASPREE-AMD results.
A weakness of this study is the reliance upon only non-
stereoscopic colour fundus photography to diagnose AMD,
without the added beneﬁt of multimodal imaging, such as optical
coherence tomography, auto-ﬂuorescence and infrared imaging
that would allow for more thorough phenotyping. In particular, our
ability to detect reticular pseudo-drusen, a risk factor for progres-
sion to late AMD, is limited.[72e74] However, the randomization
should ensure equal distribution of this limitation across both
groups. Another weakness of reliance upon colour imaging is that
nAMD may not be detectable on colour images due to the use of
anti-VEGF treatment, which can lead to underestimation of the
number of nAMD cases. This will be mitigated by including infor-
mation collected through registered adverse events in ASPREE,
validated through medical records, and also from linking the
ASPREE-AMD data to Australian Federal Government Medicare
electronic records on the use of the anti-VEGF intravitreal
injections.
5. Conclusion
The results of the study are likely to be of substantial clinical
signiﬁcance and public health importance due to a potential for the
ASPREE-AMD sub-study to identify a possible low cost therapy for
the prevention or slowing progression of AMD worldwide. The
large size of the trial will also provide information that may indi-
cate sub-groups of people who could beneﬁt more, or less, than the
overall population. Similarly, the trial will establish how the pres-
ence of various common co-morbidities inﬂuences the risk/beneﬁt
of aspirin.
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